It was hoped that as HIV treatment improved and as HIV-related public health initiatives encouraged people to be tested for the disease and seek care, that HIV-infected patients would seek care quickly. Unfortunately, a new study indicates that patients are actually sicker when they begin therapy. The study is published in the November 15 issue of Clinical Infectious Diseases, currently available online.
Warning that the H5N1 virus responsible for bird flu could still transform itself into the next human influenza pandemic, a senior United Nations specialist has stressed the need to ensure that the world can respond promptly and effectively in the case of an outbreak.
It’s almost flu season, so keep washing your hands and get a flu shot. But no matter how well we prepare, the virus stays one step ahead. Researchers now think that’s because the flu virus doesn’t vacation—it remains on duty throughout the year, traveling the globe and mixing with other strains.
The U.S. Food and Drug Administration (FDA) has approved raltegravir tablets for treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
Merck & Co., Inc., announced that the U.S. Food and Drug Administration (FDA) granted ISENTRESS TM (raltegravir) tablets accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
Smiths Detection, part of the global technology business Smiths Group, today announces it is to launch a portable detection system that will enable veterinarians to carry out on-site diagnosis of animal diseases such as foot-and-mouth and avian flu. This new technology means vets will be able to diagnose diseases in livestock and birds in the field in less than 90 minutes rather than having to send samples for laboratory analysis.
October 15, 2007, marks the fifth annual National Latino AIDS Awareness Day. On this day, the National Institute of Allergy and Infectious Diseases (NIAID) pledges to continue working toward reducing the burden of HIV/AIDS in the Latino community in the United States.
MIT Holding, Inc. (OTCBB: MITD), in collaboration with MEVLABS and Georgia Southern University, have successfully tested prototype designs of the patent pending PROVECTOR™. This small dispensable device is designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly diseases such as malaria, dengue fever, and West Nile virus.
Researchers have identified which sites and cell types within the respiratory tract are targeted by human versus avian influenza viruses, providing valuable insights into the pathogenesis of these divergent diseases.
A combination of drugs widely used to treat infections caused by HIV appears to stop brain damage caused by the virus as well, according to a study published in the Oct. 9, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.